The efficacy of orally administered isosorbide dinitrate (IS) has been questioned. Recently vasodilators have been shown to lower left ventricular filling pressure (LVFP) and raise cardiac output in heart failure. In the present study oral IS was evaluated in 12 patients with high LVFP due to heart failure. After right heart catheterization, patients with LVFP > 14 mm Hg were randomized double-blind to receive either 20 mg IS or placebo (P). Supine heart rate (HR), arterial pressure (BP), and LVFP were monitored for five hours. After this the alternate drug (P or IS) was given, followed by five more hours of monitoring. In the 12 patients after receiving IS, LVFP reached a peak reduction of 6.7 mm Hg (-26%, P < 0.005) at 30 min. Significant reduction persisted for 4.5 hours. Blood pressure fell concomitantly with the LVFP. At 60 min HR was unchanged, systolic BP was reduced by 8.9 mm Hg (P < 0.025) and diastolic BP by 6.3 mm Hg (P < 0.005). In the ten patients receiving P, control values were not significantly different from those given IS, and after receiving P, HR, BP, and LVFP failed to change significantly over the next five hours. Thus, oral IS produces a sustained reduction in LVFP and therefore merits further evaluation as chronic therapy for left ventricular failure.
EFFICACY OF THE long-acting nitrates remains a controversial issue. Isosorbide dinitrate (IS), which is used commonly in the treatment of angina pectoris, has not been found consistently effective in this disorder.'-7 Subjectivity of the anginal syndrome to various kinds of interventions makes it extremely difficult to interpret symptomatic responses to drugs.8 This factor plus the lack of uniformity and the inadequacies of protocol design have made the objective evaluation of long-acting anti-anginal agents difficult and inconclusive.9 Even though efficacy of IS given sublingually has been objectively demonstrated by hemodynamic measurements,',`considerable doubt remains regarding its activity following oral administration because of possible rapid hepatic biotransformation. '2 It has recently been shown that vasodilators reduce left ventricular filling pressure (LVFP) and improve hemodynamics in patients with refractory heart Impedance reduction failure or acute left ventricular dysfunction complicating acute myocardial infarction. '3 16 Since LVFP falls significantly during administration of the vasodilators sodium nitroprusside'3' "" 5 and nitroglycerin, ' 6 monitoring changes in LVFP should be an objective way to assess the effects of other vasodilating agents. Also, because the availability of an effective long-acting vasodilator appears desirable, the present study was initiated in an attempt to find such a drug and to evaluate LVFP monitoring as a method for demonstrating its efficacy. Our preliminary experience in patients with heart failure suggested that oral IS might be such an agent.
Methods
Patients with clinical evidence of congestive heart failure (dyspnea, S3 gallop, jugular venous distention, edema, and pulmonary venous engorgement on physical or radiological examination) secondary to primary myocardial disease, coronary artery disease, or acute myocardial infarction were selected for study. The diagnosis of primary myocardial disease was made in patients with a history of marked alcohol abuse and a lack of clinical evidence to support any other etiology for their heart disease. All but one of these patients underwent cardiac catheterization and coronary arteriography, which failed to establish any other etiology. The diagnosis of coronary artery disease was made in patients with documented previous myocardial infarction and/or significant occlusive lesions on coronary arteriography. The time course of changes in LVFP following IS and P is shown in figure 1 which depicts the mean values for the group at each point in time. Within 5-10 min after IS administration LVFP was down in several patients, and by 20 min it had fallen an average of 3 mm Hg (P < 0.01). Peak reduction of 6.7 mm Hg (-26%) (P < 0.005) was observed at 30 min. The peak effect persisted for 2 hours (P < 0.001) following drug administration when LVFP began to rise toward control levels. The last point of significant reduction of LVFP by 4.1 mm Hg (P < 0.025) was observed at 4.5 hours.
No significant change in LVFP occurred during the five hours following P, although considerable fluctuation was seen. In individual patients LVFP varied as much as 10 mm Hg above or 9 mm Hg below the control values which demonstrated a wide range of spontaneous variability.
When the two groups were compared to each other instead of their respective controls, LVFP was 3.2 mm Hg lower for IS at 25 min (P < 0.025). A peak difference of 7.7 mm Hg between IS and P occurred at 30 min (P < 0.005), and the differences between the two groups remained significant for 4.5 hours.
The reduction of LVFP following IS in patients with acute myocardial infarction was less pronounced but still significant. At 1.5 hours after IS, LVFP was down 2.8 mm Hg (P < 0.025) in patients with acute myocardial infarction and 8.5 mm Hg (P < 0.001) in those without infarction. Peak reduction was 4 mm Hg at 3 hours in infarct patients. The difference in LVFP reduction between patients with and without acute myocardial infarction was not significant. It should be noted that LVFP averaged 29.4 mm Hg before IS in non-infarct patients and only 19.3 mm Hg before IS in patients with acute myocardial infarction. Thus, it might be expected that the absolute fall of LVFP in the infarct patients would be less.
Mean values for systolic and diastolic BP changes following drug administration are shown in figure 2 . Both systolic and diastolic BP were significantly reduced after IS, but no significant change was seen after P. Although both pressures exhibited peak reductions at about 1 hour following IS, significant changes in systolic BP lasted only 2 hours, while diastolic BP was still down 3.3 mm Hg (P < 0.025) at 4 hours. Systolic BP was reduced 8.9 mm Hg (-8%), P< 0.025) 1 hour after IS, and diastolic BP was down 6.3 mm Hg (-7%, P < 0.005) at peak effect. Both Figure 2 Changes in systemic arterial blood pressure (BP) after oral isosorbide dinitrate and placebo in patients with congestive heart failure. Each point represents the mean value ± 1 standard errorfor the group. Open circles indicate statistically significant differences from time 0 (P < 0.025). Solid circles indicate insignificant differences. 27 Vasodilator therapy for heart failure has been limited by the lack of an effective long-acting agent. Our earlier experience suggested that severely ill patients could, at some point, be successfully switched from a nitroprusside infusion to long-acting nitrates. 17 The present data show that IS given orally is an effective vasodilator in patients with heart failure; therefore, this agent merits further clinical trial.
Furthermore, this study indicates that measurement of hemodynamic response in patients with heart failure is a valid and sensitive way to demonstrate pharmacological activity of vasodilating drugs. Similar methods probably should be applied to the evaluation of other vasodilators, the efficacy of which is still being questioned.
